Arcus Biosciences Arcus Biosciences (RCUS) is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer and chronic inflammatory diseases, and other diseases. In partnership with firms and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways while studying novel, biology-driven . . . This content is for paid …
Regeneron Pharmaceuticals EYLEA HD Approved by the FDA Regeneron Pharmaceuticals (REGN) announced that the U.S. FDA has approved EYLEA HD (aflibercept) Injection 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR). The recommended dose for EYLEA HD is 8 mg . . . This content is for paid subscribers. Please click here to subscribe or …
Nuvectis Pharma Nuvectis Pharma (NVCT) is a biopharmaceutical company focused on developing innovative precision targeted drugs capable of treating cancers that have yet to find treatments. The Company’s pipeline comprises two drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule in Phase 1b clinical investigating the product activity and potential treatment of platinum resistant ARID1a-mutated ovarian carcinoma . . . This content is …
Johnson & Johnson’s Janssen Pharmaceutical AKEEGA Johnson & Johnson (JNJ) owned Janssen Pharmaceutical announced that the U.S. FDA has approved AKEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone for adult patients with deleterious or suspected deleterious BRCA-positive metastatic castration-resistant prostate cancer (mCRPC), which no longer responds to androgen deprivation therapy and has spread to other …
Xenon Pharmaceuticals Q2 Financial Results On August 09, 2023 , Xenon Pharmaceuticals (XENE) reported financial results for the second quarter ended June 30, 2023, and provided a corporate update. Xenon report started with Mr. Ian Mortimer, the firm’s President and Chief Executive Officer, stating, “We are pleased to announce that patient enrollment is complete in our XEN1101 Phase 2 “X . . . This content is for paid …
CymaBay Therapeutics and Jazz Pharmaceuticals Conference Call Info CymaBay Therapeutics: Hosting a Conference Call and Live Audio Website at 4.30 PM TODAY CymaBay Therapeutics, Inc. (CBAY) - a clinical-stage biopharmaceutical company developing therapies for liver and other chronic diseases with high unmet need, announced that it will host a conference call and live audio webcast Today, Thursday . . . This content is for paid …
TG Therapeutics Conference Call TG Therapeutics (TGTX) announced that, tomorrow, Tuesday, August 1, 2023, a conference call will be held at 8.30 AM ET, to discuss the results of the second quarter 2023 and provide a business outlook for the remainder of the year. Michael S. Weiss, Chairman and Chief Executive Officer will host the call. To participate in this conference please . . …
ImmunoGen in the News WALTHAM, Mass.--(BUSINESS WIRE) --Jul. 31, 2023-- ImmunoGen (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2023. From ImmunoGen Mark Enyedy, ImmunoGen’s President and Chief Executive Officer said, “This quarter we achieved a . . . This content …
Merck and Moderna Inc Announcement Merck (MRK) and Moderna Inc (MRNA . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Syndax Pharmaceuticals and Incyte Syndax Pharmaceuticals (SNDX) and Incyte (INCY) announced positive data from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
The way drugs are being delivered into patients’ bodies have become more than ever considered important with regard to the safety and efficacy of the treatments. We consider Halozyme Biopharmaceutical is a leader in bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used …
Merck and Kintara in the NEWS Treating cancers that have no treatments should be a priority for researchers to create a treatment for them. Patients who are afflicted with untreatable deadly diseases might not have a single drop of hope in survival from these untreatable cancers. In yesterday's news, we fell on a treatment by Merck that demonstrated statistically significant and clinically meaningful improvement in …
BioMarin Pharmaceutical US FDA Approval for ROCTAVIAN On June 30, 2023, BioMarin Pharmaceutical (BMRN) announced that the U.S. FDA has approved ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) gene therapy for adults with severe hemophilia A (congenital factor VIII (FVIII) deficiency with FVIII activity < 1 IU/dL) without antibodies to adeno-associated virus serotype 5 (AAV5) detected by . . . This content is for paid subscribers. Please click here to …
CellTrans Inc FDA Approval for Lantidra for Type 1 Diabetes The U.S. Food and Drug Administration (FDA) approved CellTrans Inc treatment Lantidra, the first allogeneic pancreatic islet cellular therapy made from deceased donor pancreatic cells for the treatment of adults having type 1 diabetes. The approval is for people who are unable to approach target glycated hemoglobin (average blood glucose levels) because of current repeated episodes …
BioMarin Pharmaceutical US FDA Approved ROCTAVIAN BioMarin Pharmaceutical (BMRN) announced that the U.S. FDA approved ROCTAVIAN (valoctocogene roxaparvovec-rvox) gene therapy for adults with severe hemophilia A without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test. The one-time, single-dose infusion is the first approved gene therapy for severe hemophilia . . . This content is for paid subscribers. Please click here to subscribe …
Bayer and BlueRock Therapeutics Berlin, Germany and Cambridge, M.A., U.S.A., June 28, 2023 – Bayer AG (BAYRY) and its subsidiary firm BlueRock Therapeutics LP announced positive top-line results from a Phase I clinical trial of the investigational drug bemdaneprocel (BRT-DA01), a potential first-in-class cell therapy for Parkinson’s disease. Bemdaneprocel was well-tolerated in all 12 patients in the study to date with no major safety events. Secondary …
AIM ImmunoTech Announcement AIM ImmunoTech (AIM) - an immuno-pharma company focused on the research and development of its TLR-3 agonist Ampligen (rintatolimod) as a novel and potentially powerful therapeutic in locally advanced pancreatic cancer (“LAPC”) and metastatic pancreatic cancer, announced the required approvals from the Netherlands for Erasmus Medical Center (“Erasmus MC”) to begin a . . . This content is for paid subscribers. Please …
Celmatix Inc. Celmatix Inc., announced the identification of promising early leads in its latest drug program, aimed at developing the world’s first oral FSH receptor (FSHR) agonist drug. The innovative investigational product has the potential to revolutionize fertility treatments. The announcement coincides with the annual meeting of the European Society of Human Reproduction and Embryology (ESHRE), currently underway in Copenhagen, Denmark. From Celmatix Inc Dr. …
Arbutus Biopharma Announcement Today, June 21, 2023, Arbutus Biopharma (ABUS) announced that the first patient has been dosed in the additional treatment arm of the AB-729 Phase 2a triple combination clinical trial, which has been expanded to include a PD-1 monoclonal antibody, nivolumab. Please note that . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Vera Therapeutics Vera Therapeutics (VERA) announced that Phase 2b ORIGIN clinical trial of atacicept for IgA nephropathy met its primary and key secondary endpoints, with statistically significant and clinically meaningful reductions in proteinuria and stabilization of eGFR through week 36. The week 36 results of ORIGIN trial were presented at the 60th European Renal Association (ERA
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
